Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)

NCT05798611 is registered in ClinicalTrials.gov with Artios Pharma Ltd as lead sponsor.

NCT NCT05798611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)
Lead sponsor
Artios Pharma Ltd
Phase
Phase 2
Overall status
Terminated
Start date
September 6, 2023
Completion date
May 27, 2025
Enrollment
36 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic cancer, recurrent endometrial cancer